ARS Pharmaceuticals, Inc. SPRY
4.08
(0.07)
(1.69%)
as of 25 Sep
- Market cap
- $412.7M
- P/E
- 0.0×
Follow SPRY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(45.89%) | (92.38%) | (136.47%) | (210.37%) | |
| (27.10%) | (50.50%) | (64.42%) | (76.54%) | ||
ROIC |
(204.70%) | (296.82%) | (401.19%) | (335.65%) | |
Return on Tangible Assets |
(27.66%) | (69.05%) | (100.08%) | (141.07%) | |
Average Days of Receivables |
93.19 | 109.78 | 105.69 | 146.21 | |
Free Cash Flow per Share |
(0.87) | (1.89) | (1.76) | (1.98) | |
Free Cash Flow |
(86.02) | (186.56) | (175.07) | (196.40) | |
Capital Expenditures |
(0.64) | (15.70) | — | — | |
Piotroski F-Score |
1.00 | 1.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(14.13%) | (32.38%) | (40.39%) | (59.89%) | |
Accounts Receivable Turnover |
7.67 | 5.03 | 5.21 | 3.25 | |
Accounts Payable Turnover |
0.46 | 0.67 | 0.68 | 0.64 | |
Inventory Turnover |
3.56 | 3.01 | 3.18 | 3.28 | |
Average Days of Payables |
1,200.30 | 678.21 | 687.72 | 651.26 | |
Days of Inventory on Hand |
187.69 | 149.57 | 125.64 | 127.45 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.94% | 15.64% | 14.71% | 13.02% | |
Selling, General and Administrative Expense of Revenue |
144.05% | 273.05% | 263.90% | 243.30% | |
Share Based Compensation of Revenue |
14.44% | 26.22% | 24.47% | 26.72% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.07 | 1.00 | 0.88 | 0.91 | |
Depreciation/Fixed assets |
(4.21) | (1.69) | (1.34) | (1.01) | |
Capex/Depreciation |
0.13 | 3.78 | 0.00 | 0.00 | |
Revenue per Share |
1.44 | 0.86 | 1.00 | 1.18 | |
Operating CF per Share |
(0.86) | (1.73) | (1.76) | (1.98) | |
Capex per Share |
(0.01) | (0.16) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.19 | 0.00 | 0.00 | |
Net Profit Margin |
(56.02%) | (203.37%) | (200.10%) | (184.26%) |
Columns are period end dates